Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

CapitalLogic1 Jun. 30 at 10:17 PM

Jefferies upgraded $ABVX to Buy from Hold, raising its price target to $158 from $108. The firm cited “we’re back” sentiment, stating that key overhangs have been removed and strong clinical data should help drive value realization going forward. Jefferies also highlighted broader implications across the biotech space, referencing multiple peers including $ABBV, MRK, and others, suggesting a more constructive sector backdrop following recent updates.

1 · Reply

55X_ROI_Q1_2026 Jun. 30 at 10:15 PM

$SLS VIALE-M Phase 3 trial conducted by $ABBV for Remission Maintenance FAILED --- and not a 1 dimensional dosing regime. There were 7 different dosing Cohorts - The SAP was modified 7 times, attempting to find a dose uL amount with every combination of Injection / Intravenous and All Oral - None Work. VIALE-T Post Transplant Maintenance Phase 3 ALSO FAILED VERONA - High Risk MDS/ AML Precursor - also FAILED Meanwhile we are Seeing Miraculous ALL Pooled Survival in the SLS REGAL Phase 3 - Gps and Control on Aza VEN. Dr.s Treating the actual Patients are also on record - BAT is Toxic, Survival is not durable, extremely poor. Smart Money Knows its Gps doing what its done in all Previous Trials, Prevent Relapse and Extend Survival, with increased OS directly correlated to OS - including in 2 Phase 2 For AML REMISSION MAINTENANCE Trials. it is not complicated. buy and hold for the gold

0 · Reply

Blockwave1 Jun. 30 at 9:16 PM

$ABBV 🌊 $260 02 JUL 26 (W) CALL 100 $0.68 ➡️ $1.40 🤑 105% GAINER! ☢️ TURN MY POST NOTIFICATIONS ON! 🚨

0 · Reply

ApexEquityVault Jun. 30 at 9:13 PM

$ABBV 🩺 $260 02 JUL 26 (W) CALL 100 $0.68 ➡️ $1.40 🤑 105% GAINER! ☢️ TURN MY POST NOTIFICATIONS ON!

0 · Reply

ApexEquityVault Jun. 30 at 9:11 PM

$ABBV 🩺 $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $3.50 🤑 713% GAINER! ☢️ TURN MY POST NOTIFICATIONS ON!

0 · Reply

SellasgpsCurativeBAT11 Jun. 30 at 8:47 PM

$SLS $ABBV $BMY Vetoclax will become Obsolete after GPS FDA/EMA approval. AbbVie will be the biggest looser if another big pharmaceutical BO Sellas. 2nd biggest looser will be Onureg Bristol-Myers Squibb Co. ✌️🙏❤️‍🩹

0 · Reply

Quantumup Jun. 30 at 8:24 PM

Jefferies⬆️ $ABVX to Buy-$158 from Hold-$108 and said, We're Back: Overhang Removed, Strong Data Should Drive Value, Upgrade to BUY. CRVS SYRE PTGX - JNJ ABGE - $ABBV PALI RHHBY TEVA MRK Here's what else Jefferies had to say: https://x.com/Quantumup1/status/2072052823697801726?s=20

0 · Reply

KryptonResearch Jun. 30 at 6:47 PM

While markets are extremely focused on the inputs to the AI trade (and for good reason, as this is where the capital is flowing at the present moment). We take a look at the flip side of the AI trade. Those using AI to accelerate their businesses. Today’s investment is one of our favorites. A great business and revolutionary technology, but more importantly, one that is going to transform the lives of billions. $LLY $NVO $ABBV $PFE $JNJ Take a read: https://kryptonresearch.substack.com/p/blood-money

0 · Reply

SmartCapitall Jun. 30 at 6:09 PM

$ABBV and Genmab highlight Epkinly combo results after monotherapy failure, with the Epcore DLBCL-4 trial showing a positive signal in DLBCL. The read-through is lifting expectations into the upcoming and more critical DLBCL-2 first-line data readout. Still early-stage oncology narrative, but improving sentiment around combo strategy vs single-agent limitations.

0 · Reply

kindness123 Jun. 30 at 5:34 PM

$ABBV $LLY $MRK https://finance.yahoo.com/healthcare/articles/merck-abbvie-probed-us-lawmakers-161900980.html

0 · Reply

House committee opens probe into Merck, AbbVie China drug trials, Reuters says

MRK

2026-06-29T20:20:34.000Z - 1 day ago

AbbVie reports ‘positive’ results from Phase 3 EPCORE DLBCL-4 trial

GMAB

$AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma$

Jun 29, 2026, 4:15 PM EDT - 1 day ago

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

2026-06-29T09:20:22.000Z - 1 day ago

AbbVie announces CHMP opinion recommending approval of upadacitinib for AA

Jun 29, 2026, 3:10 AM EDT - 1 day ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jun 29, 2026, 3:00 AM EDT - 1 day ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

2026-06-26T20:55:10.000Z - 4 days ago

AbbVie says FDA approves Skyrizi for pediatric use in psoriatic disease

Jun 26, 2026, 4:50 PM EDT - 4 days ago

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Jun 26, 2026, 2:39 PM EDT - 4 days ago

Healthcare stocks have become a haven for investors ditching tech

ABSI APGE JNJ LLY MRNA SNY XBI

Jun 26, 2026, 8:00 AM EDT - 4 days ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 24, 2026, 12:51 PM EDT - 6 days ago

AbbVie's $11 Billion Immunology Bet

APGE

Jun 24, 2026, 8:00 AM EDT - 6 days ago

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

2026-06-23T12:54:44.000Z - 7 days ago

AbbVie’s Allergan Aesthetics receives approval for Boey in Canada

2026-06-23T12:22:00.000Z - 7 days ago

Apogee Therapeutics price target raised to $135 from $97 at RBC Capital

APGE

Jun 23, 2026, 8:00 AM EDT - 7 days ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

2026-06-23T11:29:50.000Z - 7 days ago

Apogee Therapeutics moved to No Rating at BofA

APGE

2026-06-23T11:04:51.000Z - 7 days ago

AbbVie price target raised to $273 from $265 at Canaccord

APGE

2026-06-23T10:24:35.000Z - 7 days ago

AbbVie announces European Commission approval for Skyrizi

2026-06-23T10:00:54.000Z - 7 days ago

AbbVie announces European Commission approval of Maviret

2026-06-23T09:46:03.000Z - 7 days ago

AbbVie announces EU approval of Skyrizi for pediatric patients

Jun 23, 2026, 5:00 AM EDT - 7 days ago

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

Jun 23, 2026, 3:00 AM EDT - 7 days ago

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

2026-06-22T21:55:09.000Z - 8 days ago

Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street

APGE EVMN

Jun 22, 2026, 10:30 AM EDT - 8 days ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

Jun 22, 2026, 10:15 AM EDT - 8 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

Jun 22, 2026, 9:00 AM EDT - 8 days ago

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 8 days ago

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 8 days ago

AbbVie Press release: M&A announcement

2026-06-22T12:24:03.000Z - 8 days ago

Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital

APGE REGN

Jun 22, 2026, 7:42 AM EDT - 8 days ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

Jun 22, 2026, 7:06 AM EDT - 8 days ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

Jun 22, 2026, 7:04 AM EDT - 8 days ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

Jun 22, 2026, 7:00 AM EDT - 8 days ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

Jun 20, 2026, 12:11 PM EDT - 10 days ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

Jun 19, 2026, 11:17 AM EDT - 11 days ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

APGE

Jun 18, 2026, 4:05 PM EDT - 12 days ago

AbbVie Declares Quarterly Dividend

Jun 16, 2026, 8:00 AM EDT - 14 days ago

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Jun 12, 2026, 3:00 AM EDT - 18 days ago

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Jun 11, 2026, 7:14 AM EDT - 19 days ago

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ALKS AMGN GILD IBB IHE JNJ KYMR

Jun 10, 2026, 11:47 AM EDT - 20 days ago

FDA Issues Complete Response Letter for AbbVie's Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Jun 9, 2026, 10:40 AM EDT - 21 days ago

AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 8, 2026, 8:00 AM EDT - 22 days ago

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Jun 3, 2026, 7:04 PM EDT - 27 days ago

British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy

Jun 3, 2026, 3:30 AM EDT - 27 days ago

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick.

BIIB LLY ROP

Jun 2, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 29, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

May 27, 2026, 6:18 PM EDT - 4 weeks ago

U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options

May 27, 2026, 3:33 PM EDT - 4 weeks ago

US FDA approves AbbVie's rare blood cancer drug

May 22, 2026, 8:00 AM EDT - 5 weeks ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 21, 2026, 6:46 PM EDT - 5 weeks ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

May 21, 2026, 4:10 PM EDT - 5 weeks ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

May 13, 2026, 2:20 PM EDT - 6 weeks ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 8, 2026, 10:00 AM EDT - 7 weeks ago

AbbVie Transcript: AGM 2026

May 6, 2026, 8:00 AM EDT - 7 weeks ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

May 5, 2026, 8:05 AM EDT - 2 months ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

May 1, 2026, 3:05 PM EDT - 2 months ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 10:03 AM EDT - 2 months ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

Apr 30, 2026, 3:00 PM EDT - 2 months ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

Apr 30, 2026, 9:00 AM EDT - 2 months ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 2 months ago

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 8:32 AM EDT - 2 months ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 7:50 AM EDT - 2 months ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:47 AM EDT - 2 months ago

AbbVie Reports First-Quarter 2026 Financial Results

Apr 28, 2026, 8:00 AM EDT - 2 months ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 7:00 AM EDT - 2 months ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 27, 2026, 8:05 AM EDT - 2 months ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 23, 2026, 4:19 PM EDT - 2 months ago

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:05 PM EDT - 2 months ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 22, 2026, 12:59 PM EDT - 2 months ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

CapitalLogic1 Jun. 30 at 10:17 PM

1 · Reply

55X_ROI_Q1_2026 Jun. 30 at 10:15 PM

0 · Reply

Blockwave1 Jun. 30 at 9:16 PM

$ABBV 🌊 $260 02 JUL 26 (W) CALL 100 $0.68 ➡️ $1.40 🤑 105% GAINER! ☢️ TURN MY POST NOTIFICATIONS ON! 🚨

0 · Reply

ApexEquityVault Jun. 30 at 9:13 PM

$ABBV 🩺 $260 02 JUL 26 (W) CALL 100 $0.68 ➡️ $1.40 🤑 105% GAINER! ☢️ TURN MY POST NOTIFICATIONS ON!

0 · Reply

ApexEquityVault Jun. 30 at 9:11 PM

$ABBV 🩺 $255 02 JUL 26 (W) CALL 100 $0.43 ➡️ $3.50 🤑 713% GAINER! ☢️ TURN MY POST NOTIFICATIONS ON!

0 · Reply

SellasgpsCurativeBAT11 Jun. 30 at 8:47 PM

0 · Reply

Quantumup Jun. 30 at 8:24 PM

0 · Reply

KryptonResearch Jun. 30 at 6:47 PM

0 · Reply

SmartCapitall Jun. 30 at 6:09 PM

0 · Reply

kindness123 Jun. 30 at 5:34 PM

$ABBV $LLY $MRK https://finance.yahoo.com/healthcare/articles/merck-abbvie-probed-us-lawmakers-161900980.html

0 · Reply

NasdaqAlpha Jun. 30 at 3:57 PM

$ABBV has taken some heat after the recent trial headlines, but I don't think the whole pipeline should be judged on one update. The market tends to swing between optimism and disappointment with biotech, while the longer-term picture usually takes much more time to play out. I'm watching how investors respond after the dust settles rather than reacting to a single headline.

0 · Reply

55X_ROI_Q1_2026 Jun. 30 at 3:09 PM

$SLS $GILD $ABBV Great Day to BUY $SLS Been 50 Days since the 78th Event --- 22 Day Per Event Rate 80th EVENT IS NOW TRULY IMMINENT ... ALONG WITH BALLISTIC SHARE PRICE LAUNCH.

0 · Reply

55X_ROI_Q1_2026 Jun. 30 at 3:04 PM

$SLS $GILD $ABBV Been 50 Days since the 78th Event --- 22 Day Per Event Rate 80th EVENT IS NOW TRULY IMMINENT ... ALONG WITH BALLISTIC SHARE PRICE LAUNCH. 60th Event / Share Price Launch 72nd Event / Share Price Launch 78th Event / Share Price Launch 80th Event / Share Price Will Be Launching IMMINENTLY. Just Look at the Market Action Since the 60th Event, when the IDMC Unblinded Actual Phase 3 Median Overall Survival and Immune Response Data - from the Ongoing P3. - Share Price 10x, Market Cap +12X Cash on Hand up 10x Runway to 2030, Institutional Funds from 39 to 167 - not 1 Short only. Smarter Money than US Knows Gps is Golden.

0 · Reply

Oldpuck Jun. 30 at 2:59 PM

$ABBV Rotation didn't last very long

0 · Reply

NasdaqFrontier Jun. 30 at 2:56 PM

$ABBV is making waves with the latest phase 3 results and aggressive M&A strategy. I wasn't expecting such a steady reaction to the acquisition news, but it seems the market is focused on the long-term pipeline strength. Still, I’m not chasing the current level. Stalking this base to see if it holds support before I even consider adding to the position.

0 · Reply

Blockwave1 Jun. 30 at 2:44 PM

Telegram channel: https://t.me/BlockWave10 $ABBV $QQQ $SPY $AAPL remembers this guy? 😂🔥 He’s been absolutely crushing the setups! The trust and consistency have been incredible, and I truly appreciate the support. 💯 I’ll keep doing my part and bringing the best opportunities. Much love to everyone who’s been rocking with us! ❤️🌊

0 · Reply

NvidiaKing Jun. 30 at 2:02 PM

$ABBV this is a POS 🐓

0 · Reply

Quantumup Jun. 30 at 11:13 AM

Guggenheim reiterated Best Idea $ABVX at Buy-$175 SYRE CRVS PALI PTGX - $JNJ APGE - $ABBV RHHBY MRK TEVA Here's what Guggenheim had to say in its note to investors: https://x.com/Quantumup1/status/2071914563683901822?s=20

0 · Reply

Quantumup Jun. 30 at 10:24 AM

BTIG⬆️ $ABVX-$175,⬆️PoS for obefazimod in UC to 95% & CD to 85% and reiterated at Buy PTGX - $JNJ APGE - $ABBV SYRE PALI RHHBY MRK TEVA Here's what BTIG said in its note to investors: https://x.com/Quantumup1/status/2071902283541999785?s=20

0 · Reply

notreload_ai Jun. 30 at 9:00 AM

$ABBV, $GMAB new drug combo helps lymphoma patients live longer without worsening disease, cutting risk by ~60%—without chemotherapy. https://notreload.xyz/xy/abbvie-genmab-positive-phase-3-results-in-r-r-dlbcl/

0 · Reply

55X_ROI_Q1_2026 Jun. 30 at 3:55 AM

$SLS $GILD $ABBV r/gabri71 deep cut In conclusions the Authors state ‘The longer OS observed in patients who subsequently underwent allo-HSCT refrains the fact that stem cell transplantation after the achievement of a CR/CRi is still the only viable, and possibly curative, option for patients with r/R AML (and this was around 20 months of mOS after reaching CR2 status)’. 20 month MOS FOR CR2 getting transplant, 8.8 month MOS for CR2 not getting Transplant, on BAT. https://www.reddit.com/r/sellaslifesciences/s/dWtZbCNCoh

0 · Reply

SellasgpsCurativeBAT11 Jun. 30 at 3:47 AM

$ABBV $BMY $LLY $PFE $SLS BIG MOVES IN BIOTECH INNOVATION IS MERGING. SLS Next up. ✌️🙏❤️‍🩹

0 · Reply

Market Cap	447.62B
Revenue (ttm)	61.16B
Net Income (ttm)	4.23B
EPS (ttm)	N/A
PE Ratio	24.86
Forward PE	17.75
Profit Margin	6.91%
Debt to Equity Ratio	-11.02

Volume	6,999,405
Avg Vol	7,321,322
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	96%
Beta	0.32
Analysts	Strong Sell
Price Target	$250.97